

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康臣藥業集團有限公司
CONSUN PHARMACEUTICAL GROUP LIMITED

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1681)

Voluntary Announcement Appointment of Scientific Advisor

The board (the “**Board**”) of directors (the “**Directors**”) of Consun Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the Company entered into a consulting services agreement with Professor Jonathan Barratt (“**Professor Barratt**”) in March 2025, and he would provide services to the Group as a scientific advisor.

The biographies of Professor Barratt are set out as follows:

Professor Barratt is the Mayer Professor of Renal Medicine and Consultant Nephrologist of University of Leicester and leads the Mayer IgA Nephropathy Research Group at the University of Leicester. He is also the IgA nephropathy Rare Disease Group lead for the United Kingdom National Registry of Rare Kidney Diseases (RaDaR) and the convener of the steering committee of The International IgA Nephropathy Network. Professor Barratt regularly provides advice and guidance to companies submitting applications to the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA). He leads the IgAN group updating the international KIDGO guidelines on the clinical management of glomerular disease. Professor Barratt is also an editorial board member of authoritative journals, such as “Kidney International” and “Clinical Journal of the American Society of Nephrology”, and has made outstanding contributions to the diagnosis and treatment of kidney disease and the development of new drugs.

The scope of services to be provided by Professor Barratt to the Group are including but not limited to (i) render professional opinion as a scientific advisor; (ii) chair seminars or lectures organised or sponsored by the Company; (iii) provide academic and/or educational speech services; and (iv) participate in protocol discussion organised by the Company and provide guidance.

The Board would like to welcome Professor Barratt for joining the Company. The Board believes that Professor Barratt’s expertise and experience will be beneficial to the Group’s long-term development in the future.

Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Consun Pharmaceutical Group Limited
An Meng
Chairman

Hong Kong, 30 March 2025

As at the date of this announcement, the Board comprises Mr. An Meng and Professor Zhu Quan as executive Directors; Dr. Zhang Lihua as non-executive Director; Mr. Feng Zhongshi, Professor Li Yikai and Mr. Li Zhuoguang as independent non-executive Directors.